The FirstTake Podcast – Pharma’s pandemic takes a new twist

FirstWord Pharma PLUS editors Matthew Dennis and Simon King discuss the potential impact of the Omicron variant on the efficacy of COVID-19 vaccines, how GlaxoSmithKline and Sanofi are making moves to keep their vaccines portfolios at the cutting edge of R&D and whether there is a meaningful future for Merck & Co.’s COVID-19 antiviral molnupiravir after this week’s close-run AdCom vote.

Please subscribe, like and share and most importantly, thanks for listening.

Listen on Apple podcasts and Spotify

To read more ViewPoints articles, click here.